ストックスクリーナーアプリを入手
10.58
0.85%
-0.03
前日終値:
$10.61
開ける：
$10.49
24時間の取引高:
14,341
Relative Volume:
0.05
時価総額：
$538.51M
収益：
$62.02M
当期純損益:
$-45.65M
株価収益率:
-11.50
EPS:
-0.92
ネットキャッシュフロー:
$-9.60M
1週間 パフォーマンス:
-6.49%
1か月 パフォーマンス:
+18.07%
6か月 パフォーマンス:
+6.48%
1年 パフォーマンス:
+22.61%
1日の値動き範囲:
$10.46
$10.63
1週間の範囲:
$10.46
$11.27
52週間の値動き範囲:
$7.44
$11.82
Theravance Biopharma Inc Stock (TBPH) Company Profile
名前
Theravance Biopharma Inc
セクター
電話
650-808-6000
住所
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
10.58 | 538.51M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.57 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.81 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.11 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
582.69 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
272.33 | 27.80B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 開始されました | BTIG Research | Buy |
| 2024-01-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-15 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-08-25 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-10-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 開始されました | JP Morgan | Overweight |
| 2020-06-15 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 開始されました | Cowen | Outperform |
| 2020-01-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-06 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-29 | 再開されました | Piper Jaffray | Overweight |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-06-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 繰り返されました | Needham | Buy |
| 2016-12-21 | 開始されました | Needham | Buy |
| 2016-11-03 | 開始されました | Piper Jaffray | Overweight |
| 2016-10-12 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 開始されました | Guggenheim | Buy |
| 2016-06-20 | 繰り返されました | Leerink Partners | Outperform |
| 2016-05-12 | 開始されました | Leerink Partners | Outperform |
| 2016-05-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
すべてを表示
Theravance Biopharma Inc (TBPH) 最新ニュース
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance and Mylan settle patent dispute with Eugia Pharma - MSN
theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa
Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha
Theravance BiopharmaTheravance And Mylan Enter Settlement Agreement With EugiaSEC Filing - marketscreener.com
Theravance Biopharma Settles Patent Litigation with Eugia - TipRanks
theravance biopharma settles patent litigation with eugia pharma - Investing.com
(TBPH) Investment Analysis - news.stocktradersdaily.com
Theravance Biopharma Sells Remaining Trelegy Royalties to GSK for $225 Million - Global Legal Chronicle
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - sharewise
ProShare Advisors LLC Takes Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLC - Defense World
Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - marketscreener.com
Theravance Biopharma Sells Trelegy Royalty Interest to GSK - TipRanks
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in T - GuruFocus
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - Eagle-Tribune
Ameriprise Financial Inc. Cuts Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Nuveen Asset Management LLC Buys 48,635 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Deutsche Bank AG Purchases 15,608 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Jane Street Group LLC Has $493,000 Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Bank of America Corp DE Increases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - Barchart.com
(TBPH) On The My Stocks Page - news.stocktradersdaily.com
Northern Trust Corp Has $3.67 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance
Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and Ampreloxetine - Investing.com Canada
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by StockNews.com - Defense World
When (TBPH) Moves Investors should Listen - news.stocktradersdaily.com
Theravance Biopharma to Participate in an Upcoming Investor Conf - GuruFocus
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune
Price T Rowe Associates Inc. MD Buys 9,315 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Dimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma Announces Ampreloxetine Presentations at th - GuruFocus
Theravance Biopharma, Inc. Announces Ampreloxetine Presentations At the International MSA Congress - marketscreener.com
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - TradingView
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - Stock Titan
Theravance Biopharma: Promising Future with Strong Product Pipeline and Market Expansion - TipRanks
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights - GuruFocus
Tower Research Capital LLC TRC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - The AM Reporter
Wells Fargo & Company MN Has $204,000 Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Progress Amid Challenges - GuruFocus
Theravance Biopharma Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecast - Investing.com
Theravance Biopharma Q1 2025 slides: revenue growth amid widening losses - Investing.com Canada
Theravance Biopharma earnings missed by $0.05, revenue topped estimates - Investing.com Canada
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecast By Investing.com - Investing.com India
Theravance Biopharma Inc (TBPH) 財務データ
収益
当期純利益
現金流量
EPS
0.06%
0.26%
大文字化:
|
ボリューム (24 時間):